Linagliptin/Metformin Hydrochloride

利格列汀/盐酸二甲双胍

Report date: 2026/03/23 20:03:44

Base Information

Drug NameLinagliptin/Metformin Hydrochloride
Drug Alias Name利格列汀•盐酸二甲双胍Metformin Hydrochloride and Linagliptin利格列汀和盐酸二甲双胍Metformin Hydrochloride/LinagliptinLinagliptin • Metformin Hydrochloride +[15] 
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsDipeptidyl peptidase IVProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2012/01/30
Country/TerritoryCanadaUnited StatesVietnam +[9] 
CombinationsYes LinagliptinMetformin Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesDong Wha Pharm Co LtdGC Biopharma CorpBoehringer Ingelheim (Schweiz) Gmbh +[4] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Trading (Shanghai) Co Ltd
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD11
Related LinksKEGG